The US Food and Drug Administration’s negative review for Intercept Pharmaceuticals’s obeticholic acid has set off questions about the fate of other non-alcoholic steatohepatitis (NASH) drug hopefuls.
Among them is Zydus Lifesciences Limited, the sole Indian company evaluating a New Chemical Entity saroglitazar magnesium against chronic...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?